Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-05251749 in Healthy Adults
NCT02443740Phase 1Completed
- Sponsor
- Biogen
- Start
- May 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-05251749 in Alzheimer's disease (AD) and Parkinson's disease (PD) (3 arms), sponsored by Biogen. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs), Number of Participants With Laboratory Abnormalities and 4 more. Started May 2015; status: completed.
02
Drugs
PF-05251749
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02443740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02443740.